Frederic Newman, MD
Gastroenterology · Pensacola, FLNPI 1568443299
Payments from drug & device makers
Across 487 payments — averaging $3930.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$786K
- AbbVie$398K
- Eli Lilly$364K
- Genentech, Inc.$194K
- Novartis$99K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- plus $33K from 31 others
Across 12 payments — averaging $1588.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$19K
What the payments were for
- Travel & lodging$1,46923%
- Food & beverage$4,80176%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 108 | $786,016 |
| AbbVie(2 entities) | 108 | $397,916 |
| Eli Lilly | 41 | $363,677 |
| Genentech, Inc. | 36 | $194,239 |
| Novartis | 4 | $98,730 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $40,797 |
| AstraZeneca | 7 | $28,097 |
| Apollo Endosurgery US Inc | 6 | $1,618 |
| Johnson & Johnson | 47 | $674 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $487 |
| E.r. Squibb & Sons, L.L.C. | 2 | $228 |
| Bristol Myers Squibb | 10 | $176 |
| Gilead | 6 | $128 |
| Ironwood Pharmaceuticals, Inc | 8 | $121 |
| Medtronic(2 entities) | 3 | $93 |
| Covidien LP | 1 | $89 |
| Boston Scientific | 1 | $86 |
| Lumendi LLC | 1 | $86 |
| Pfizer | 5 | $70 |
| Nestle Healthcare Nutrition Inc. | 3 | $68 |
| Axonics, Inc. | 4 | $68 |
| Janssen Scientific Affairs, LLC | 1 | $66 |
| Cook Medical LLC | 1 | $63 |
| Sanofi | 3 | $59 |
| Merck | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Phathom Pharmaceuticals, Inc. | 4 | $41 |
| Shionogi Inc | 2 | $37 |
| Ardelyx, Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,914,058 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 81 | $80,356 |
| CreonLipase/Protease/Amylase | 11 | $46,491 |
| MovantikNaloxegol Oxalate | 20 | $9,573 |
| Mesalamine ErMesalamine | 18 | $5,078 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 20 | $3,269 |
| Budesonide DrBudesonide | 21 | $2,790 |
| Pantoprazole Sodium | 223 | $2,593 |
| Ursodiol | 17 | $2,421 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 12 | $2,027 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 28 | $1,790 |
| Omeprazole | 80 | $1,024 |
| Famotidine | 65 | $909 |
| Colestipol Hcl | 11 | $874 |
| Dicyclomine Hcl | 25 | $700 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 41 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $397,916 | $126,84692 claims |
| Braintree Laboratories, Inc.Sutab | $19 | $3,26920 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $16 | $2,02712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Pensacola
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
- Henry LevineOrlando$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.